166 related articles for article (PubMed ID: 36056891)
41. Severe monobacterial necrotizing soft tissue infection by group A Streptococcus: A surgical emergency.
Lanitis S; Khan MA; Sgourakis G; Kontovounisios C; Papaconstandinou T; Karaliotas C
Asian Pac J Trop Biomed; 2012 Mar; 2(3):250-2. PubMed ID: 23569908
[TBL] [Abstract][Full Text] [Related]
42. [A case of invasive group A Streptococcus infection which was successfully treated with linezolid].
Nakamura S; Yanagihara K; Kaneko Y; Ohno H; Higashiyama Y; Miyazaki Y; Hirakata Y; Tomono K; Tashiro T; Kohno S
Kansenshogaku Zasshi; 2004 May; 78(5):446-50. PubMed ID: 15211868
[TBL] [Abstract][Full Text] [Related]
43. Impact of Empiric Linezolid for Necrotizing Soft Tissue Infections on Duration of Methicillin-Resistant
Lehman A; Santevecchi BA; Maguigan KL; Laconi N; Loftus TJ; Mohr AM; Shoulders BR
Surg Infect (Larchmt); 2022 Apr; 23(3):313-317. PubMed ID: 35133888
[No Abstract] [Full Text] [Related]
44. Case 28-2002: a traveler with a rapidly progressive soft-tissue infection.
Johnson JR; Gandhi R
N Engl J Med; 2003 Jan; 348(2):176-7; author reply 176-7. PubMed ID: 12519934
[No Abstract] [Full Text] [Related]
45. Streptococcal toxic shock-like syndrome.
Wolf JE; Rabinowitz LG
Arch Dermatol; 1995 Jan; 131(1):73-7. PubMed ID: 7826100
[TBL] [Abstract][Full Text] [Related]
46. Toxic Shock Syndrome Toxin 1 Evaluation and Antibiotic Impact in a Transgenic Model of Staphylococcal Soft Tissue Infection.
Sharma H; Turner CE; Siggins MK; El-Bahrawy M; Pichon B; Kearns A; Sriskandan S
mSphere; 2019 Oct; 4(5):. PubMed ID: 31597722
[TBL] [Abstract][Full Text] [Related]
47. Steroids in the treatment of group A streptococcal necrotizing soft tissue infection.
May AK; Daniels TL; Obremskey WT; Kaiser AB; Talbot TR
Surg Infect (Larchmt); 2011 Feb; 12(1):77-81. PubMed ID: 21171810
[TBL] [Abstract][Full Text] [Related]
48. Group B streptococcal necrotizing fasciitis and toxic shock-like syndrome: a case report and review of the literature.
Crum NF; Wallace MR
Scand J Infect Dis; 2003; 35(11-12):878-81. PubMed ID: 14723367
[TBL] [Abstract][Full Text] [Related]
49. The flesh-eating bacterium: what's next?
Stevens DL
J Infect Dis; 1999 Mar; 179 Suppl 2():S366-74. PubMed ID: 10081509
[TBL] [Abstract][Full Text] [Related]
50. Case Report: Therapeutic Strategy With Delayed Debridement for Culture-Negative Invasive Group A Streptococcal Infections Diagnosed by Metagenomic Next-Generation Sequencing.
He W; Wu C; Zhong Y; Li J; Wang G; Yu B; Xu P; Xiao Y; Tang T
Front Public Health; 2022; 10():899077. PubMed ID: 35646803
[TBL] [Abstract][Full Text] [Related]
51. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
Parks T; Wilson C; Curtis N; Norrby-Teglund A; Sriskandan S
Clin Infect Dis; 2018 Oct; 67(9):1434-1436. PubMed ID: 29788397
[TBL] [Abstract][Full Text] [Related]
52. Comparison of Adjuvant Clindamycin vs Linezolid for Severe Invasive Group A
Heil EL; Kaur H; Atalla A; Basappa S; Mathew M; Seung H; Johnson JK; Schrank GM
Open Forum Infect Dis; 2023 Dec; 10(12):ofad588. PubMed ID: 38149106
[TBL] [Abstract][Full Text] [Related]
53. Murine Soft Tissue Infection Model to Study Group A Streptococcus (GAS) Pathogenesis in Necrotizing Fasciitis.
Ravins M; Ambalavanan P; Biswas D; Tan RYM; Lim KXZ; Kaufman Y; Anand A; Sharma A; Hanski E
Methods Mol Biol; 2022; 2427():185-200. PubMed ID: 35619035
[TBL] [Abstract][Full Text] [Related]
54. Severe group A streptococcal toxic shock syndrome presenting as primary peritonitis: a case report and brief review of the literature.
Tilanus AM; de Geus HR; Rijnders BJ; Dwarkasing RS; van der Hoven B; Bakker J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e208-12. PubMed ID: 19914115
[TBL] [Abstract][Full Text] [Related]
55. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model.
Tarnutzer A; Andreoni F; Keller N; Zürcher C; Norrby-Teglund A; Schüpbach RA; Zinkernagel AS
Clin Microbiol Infect; 2019 Apr; 25(4):512.e7-512.e13. PubMed ID: 30025835
[TBL] [Abstract][Full Text] [Related]
56. Group A streptococcal bacteremias in Southwest Finland 2007-2018: epidemiology and role of infectious diseases consultation in antibiotic treatment selection.
Vilhonen J; Vuopio J; Vahlberg T; Gröndahl-Yli-Hannuksela K; Rantakokko-Jalava K; Oksi J
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1339-1348. PubMed ID: 32096108
[TBL] [Abstract][Full Text] [Related]
57. Revisiting the inoculum effect for Streptococcus pyogenes with a hollow fibre infection model.
Marum D; Manning L; Raby E
Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2137-2144. PubMed ID: 33948751
[TBL] [Abstract][Full Text] [Related]
58. Group A streptococcus.
Martin JM; Green M
Semin Pediatr Infect Dis; 2006 Jul; 17(3):140-8. PubMed ID: 16934708
[TBL] [Abstract][Full Text] [Related]
59. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review.
Cawley MJ; Briggs M; Haith LR; Reilly KJ; Guilday RE; Braxton GR; Patton ML
Pharmacotherapy; 1999 Sep; 19(9):1094-8. PubMed ID: 10610017
[TBL] [Abstract][Full Text] [Related]
60. [Invasive streptococcal (group A) infection: an outlook (review)].
Briko NI; Malyshev NA; Pokrovskiĭ VI
Ter Arkh; 2004; 76(11):65-8. PubMed ID: 15658541
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
